SCHEMBL4908557

SCHEMBL4908557

N#Cc1c(-c2cccnc2)nc(NC2CC2)[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.46
ADORA1 P30542 3/20 0.46
ADORA2B P29275 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
XDH P47989 1/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
DHODH Q02127 1/20 0.42
PDE10A Q9Y233 1/20 0.42
PIM1 P11309 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906948 0.82 ADORA1 (0.46) ADORA2AADORA1ADORA2BALDH1A1CYP1A2
SCHEMBL4907254 0.81 ADORA1 (0.49) ADORA2AADORA1ADORA2BALDH1A1CYP1A2
SCHEMBL4899405 0.81 CYP11B1 (0.43) ALDH1A1CYP1A2CYP2C9HPGDXDH
SCHEMBL4905878 0.80 LMNA (0.56) CA12CA1CA2CA9ALDH1A1
SCHEMBL4907452 0.80 MEN1 (0.53) ADORA1ADORA2BALDH1A1CYP1A2CYP2C9
SCHEMBL4903905 0.80 BRD4 (0.48) ADORA2AADORA1CA12CA2CA9
SCHEMBL4907124 0.78 HPGD (0.45) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL4898075 0.77 BRD4 (0.44) ALDH1A1CYP1A2CYP2C9HPGDXDH
SCHEMBL4898304 0.76 ALDH1A1 (0.42) CA12CA2CA9ALDH1A1CYP1A2
SCHEMBL4908292 0.74 KMT2A (0.56) ADORA2AADORA1ADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA2A 837/4885ADORA1 529/4885ADORA2B 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.